Featured Listing

AlphaMaven

Company Logo'

Venture Capital Featured Listing

BrookDell Partners

Back

Private Equity

Andrea Alms Video: Money In Motion 90 - JP Morgan Healthcare Conference 2024

January 2024 - Private Equity

posted by BrookDell Partners
1yr ago 1

TRANSCRIPT Hello, my name is Andrea Alms. I'm technology investor and financial manager and this is your money in motion. JPMorgan Health Care Conference 2020 1000s of health care leaders will descend on San Francisco for the annual conference to discuss some of the industry's most pressing topics, ranging from artificial intelligence and Medicare Advantage enrollment to health system investment strategies, according to Bain and Company, as the year 2022 ended, the number of strategic health care deals have declined by more than 30%, and the average deal size has fallen by about 15% in line with the overall corporate M&A activity.


It was largely a wait and see year. Then two megadeals were announced in the fourth quarter, namely GAO's $16.6 billion acquisition of a biomed in November and Amgen's $28 billion acquisition of Horizon in December. According to Leerink and Deal Logic, health care M&A activity declined in 2023, due in part to rising interest rates and persistent economic uncertainty. Pharmaceutical subsector remained the most active subsector of health care and represents 58% of the deal value and 33 33% of the number of health care transactions in 2023 versus 36% of deal value and 27% of number of health care transactions in 2022.


M&A themes Winners and losers. Oncology was the most active therapeutic area for M&A, with 11 deals totaling 49 billion in deal value. That is excluding the $6 billion deal. Pfizer announced $43 billion acquisition. A secret Rare diseases was the second most active therapeutic area for M&A, with nine deals totaling 13 billion in total deal value. This was the exclusion of BIOGEN'S $7 billion acquisition of Reata Immunology was the third most active therapeutic area for M&A, with seven deals totaling 25 billion in total deal.


Excluding this was excluding Merck's $10 billion acquisition of Prometheus Health care services transaction activity was significantly down for 20 2022, with 27 deals totaling 44 billion in deal value versus 71 deals it totaling 89 billion in 22, resulting in -44 deals and -49% health care. IT activity is also depressed for 2022, with six deals totaling 5 billion in deal value versus 21 deals totaling 25 billion in deal value in 2022, resulting in -15 deals and a -80% deal value from 2022 to 2023. Thank you. This is your money, your money, in motion.


ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.